Aim: This meta-analysis aimed to document the impact of primary tumor site on antiEGFR monoclonal antibody (mAb) benefit in metastatic colorectal cancer. Materials & methods: Tumors with metastatic left-sided colorectal cancer (LCC) were compared with tumors with metastatic right-sided colon cancer (RCC) with respect to anti-EGFR mAb objective response rate (ORR), overall survival (OS) and progression-free survival (PFS) benefit. Results: Comparing LCC with RCC, LCC was found to have significantly superior antiEGFR mAb ORR (p < 0.00001), OS (p < 0.00001) and PFS (p < 0.00001) benefit. Additionally, anti-EGFR mAb therapy significantly improved both OS and PFS for LCC compared with no anti-EGFR mAb therapy, but not for RCC. The test of interaction was also apparent for OS (p = 0.0002) and PFS (p = 0.0002). Conclusion: This meta-analysis demonstrated that LCC had markedly superior anti-EGFR mAb treatment benefit compared with RCC.
基金：
Shihezi University Youth Science and Technology Talent Cultivation Plan of Foundational Applications Research [2015ZRKXYQ19]
第一作者单位：[1]Shihezi Univ, Sch Med, Dept Pathol, Shihezi, Xinjiang, Peoples R China[2]Shihezi Univ, Sch Med, Key Lab Xinjiang Endem & Ethn Dis, Shihezi, Xinjiang, Peoples R China[3]Shihezi Univ, Sch Med, Affiliated Hosp 1, Dept Pathol, Shihezi, Xinjiang, Peoples R China
通讯作者：
通讯机构：[1]Shihezi Univ, Sch Med, Dept Pathol, Shihezi, Xinjiang, Peoples R China[2]Shihezi Univ, Sch Med, Key Lab Xinjiang Endem & Ethn Dis, Shihezi, Xinjiang, Peoples R China[3]Shihezi Univ, Sch Med, Affiliated Hosp 1, Dept Pathol, Shihezi, Xinjiang, Peoples R China[5]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Oncol, Wuhan, Hubei, Peoples R China[6]Capital Med Univ, Beijing Chaoyang Hosp, Dept Pathol, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Li Dandan,Fu Qiang,Li Man,et al.Primary tumor site and anti-EGFR monoclonal antibody benefit in metastatic colorectal cancer: a meta-analysis[J].FUTURE ONCOLOGY.2017,13(12):1115-1127.doi:10.2217/fon-2016-0468.
APA：
Li, Dandan,Fu, Qiang,Li, Man,Li, Jun,Yin, Can...&Li, Feng.(2017).Primary tumor site and anti-EGFR monoclonal antibody benefit in metastatic colorectal cancer: a meta-analysis.FUTURE ONCOLOGY,13,(12)
MLA：
Li, Dandan,et al."Primary tumor site and anti-EGFR monoclonal antibody benefit in metastatic colorectal cancer: a meta-analysis".FUTURE ONCOLOGY 13..12(2017):1115-1127
